Management of Hypertension in the Asia-Pacific Region: A Structured Review

被引:0
作者
Abdul R. A. Rahman
Jose Donato A. Magno
Jun Cai
Myint Han
Hae-Young Lee
Tiny Nair
Om Narayan
Jiampo Panyapat
Huynh Van Minh
Rohit Khurana
机构
[1] An Nur Specialist Hospital,Division of Cardiovascular Medicine, Philippine General Hospital, Cardiovascular Institute
[2] University of the Philippines College of Medicine,Hypertension Center
[3] Angeles University Foundation Medical Center,Department of Internal Medicine
[4] Fuwai Hospital,Department of Internal Medicine
[5] Grand Hantha International Hospital,The Harley Street Heart and Vascular Center
[6] Seoul National University Hospital,undefined
[7] PRS Hospital,undefined
[8] The Northern Hospital,undefined
[9] Bhumibol Adulyadej Hospital,undefined
[10] Hue University of Medicine and Pharmacy,undefined
[11] Gleneagles Hospital,undefined
来源
American Journal of Cardiovascular Drugs | 2024年 / 24卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
This article reviews available evidence regarding hypertension management in the Asia-Pacific region, focussing on five research questions that deal with specific aspects: blood pressure (BP) control, guideline recommendations, role of renin–angiotensin–aldosterone system (RAAS) inhibitors in clinical practice, pharmacological management and real-world adherence to guideline recommendations. A PubMed search identified 2537 articles, of which 94 were considered relevant. Compared with Europeans, Asians have higher systolic/diastolic/mean arterial BP, with a stronger association between BP and stroke. Calcium channel blockers are the most-commonly prescribed monotherapy in Asia, with significant variability between countries in the rates of angiotensin-converting enzyme inhibitors (ACEis)/angiotensin-receptor blockers (ARBs) and single-pill combination (SPC) use. In clinical practice, ARBs are used more commonly than ACEis, despite the absence of recommendation from guidelines and clinical evidence supporting the use of one class of drug over the other. Ideally, antihypertensive treatment should be tailored to the individual patient, but currently there are limited data on the characteristics of hypertension in Asia-Pacific individuals. Large outcome studies assessing RAAS inhibitor efficacy and safety in multi-national Asian populations are lacking. Among treated patients, BP control rates were ~ 35 to 40%; BP control in Asia-Pacific is suboptimal, and disproportionately so compared with Western nations. Strategies to improve the management of hypertension include wider access/availability of affordable treatments, particularly SPCs (which improve adherence), effective public health screening programs targeting patients to drive health-seeking behaviours, an increase in physician/patient awareness and early implementation of lifestyle changes. A unified Asia-Pacific guideline on hypertension management with pragmatic recommendations, particularly in resource-limited settings, is essential.
引用
收藏
页码:141 / 170
页数:29
相关论文
共 623 条
[21]  
Gholap N(2018)A case control association study of ACE gene polymorphism (I/D) with hypertension in Punjabi population from Faisalabad, Pakistan Clin Exp Hypertens. 40 2154-258
[22]  
Davies M(2010)Association of angiotensinogen gene M235T and angiotensin-converting enzyme gene I/D polymorphisms with essential hypertension in Han Chinese population: a meta-analysis J Hypertens 28 241-83
[23]  
Patel K(2008)Genetic variation in the ASIC3 gene influences blood pressure levels in Taiwanese J Hypertens 26 252-288
[24]  
Sattar N(2018)Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China Lipids Health Dis 17 80-89
[25]  
Khunti K(2008)Influence of CYP11B2 gene polymorphism on the prevalence of hypertension and the blood pressure in Japanese men: interaction with dietary salt intake J Nutrigenet Nutrigenom 1 282-465
[26]  
Kaul U(2008)Association of eNOS Glu298Asp gene polymorphism with essential hypertension in Asian Indians Clin Chim Acta 387 83-226
[27]  
Bhagwat A(2019)Association between CYP3A4 gene rs4646437 polymorphism and the risk of hypertension in Chinese population: a case-control study Biosci Rep. 39 461-41
[28]  
Omboni S(2012)Association of polymorphisms in the AGT gene with essential hypertension in the Chinese population J Renin Angiotensin Aldosterone Syst 13 221-771
[29]  
Kaul U(2008)Association of polymorphisms of ABCA1 and ROS1 with hypertension in Japanese individuals Int J Mol Med 21 35-26
[30]  
Omboni S(2020)Association between the A46G polymorphism (rs1042713) in the β2-adrenergic receptor gene and essential hypertension susceptibility in the Chinese population: a PRISMA-compliant meta-analysis Medicine (Baltimore) 99 766-879